Targeting Dyrk1a to treat Alzheimer's disease
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
['FUNDING_R01'] · UNIVERSITY OF ARIZONA · NIH-10813029
This study is testing a new treatment for Alzheimer's disease that aims to help improve memory and thinking by using a special compound called Dyr219, which works on several important factors that contribute to the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-10813029 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment approach for Alzheimer's disease by inhibiting the Dyrk1a protein, which is involved in multiple pathways that contribute to the disease. The study aims to develop a compound called Dyr219 that can simultaneously modulate tau, amyloid, and neuroinflammatory pathways, which are all critical in the progression of Alzheimer's. By using animal models, researchers will assess the effectiveness of Dyr219 in improving cognitive function and reducing pathological features associated with Alzheimer's. The goal is to find a treatment that addresses the complexity of the disease rather than targeting a single component.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly slows down or modifies the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting multiple pathways in Alzheimer's disease, indicating potential for success.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HULME, CHRISTOPHER — UNIVERSITY OF ARIZONA
- Study coordinator: HULME, CHRISTOPHER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease